ACAD
31.77
-0.8
-2.46%
AEMD
0.26
+0.01
+2.00%
APRI
1.22
-0.02
-1.61%
ARNA
4.52
-0.14
-3.00%
ATEC
1.36
+0.01
+0.74%
CFN
59.75
-0.23
-0.38%
CNAT
5.34
+0.02
+0.38%
CRXM
0.2
+0.02
+11.11%
CYTX
0.47
-0.01
-1.19%
DXCM
57.92
-0.19
-0.33%
GNMK
13.18
+0.09
+0.69%
HALO
13.89
-0.12
-0.86%
ILMN
196.69
+2.8
+1.44%
INNV
0.25
+0.01
+4.17%
INO
8.62
+0.12
+1.41%
ISCO
0.06
0.00
0.00%
ISIS
71.25
+0.27
+0.37%
LGND
54.86
-0.97
-1.74%
LPTN
2.97
0.00
0.00%
MBVX
1.1
-0.15
-12.00%
MEIP
3.69
-0.1
-2.64%
MNOV
3.52
-0.12
-3.17%
MRTX
19.27
-0.15
-0.77%
MSTX
0.48
+0.00
+0.04%
NBIX
31.71
+0.13
+0.41%
NUVA
46.93
-0.26
-0.55%
ONCS
0.4
+0.00
+0.25%
ONVO
6.32
-0.05
-0.78%
OREX
5.4
+0.12
+2.27%
OTIC
32.83
+3.49
+11.90%
QDEL
24.26
-0.04
-0.16%
RCPT
110.23
+3.01
+2.80%
RGLS
18.53
+0.27
+1.48%
RMD
65.44
+3.58
+5.79%
SCIE
0.01
0.00
-7.75%
SPHS
0.45
+0.00
+1.02%
SRNE
9.96
-0.03
-0.30%
TROV
5.82
0.00
-0.06%
VICL
1.04
+0.01
+0.96%
VOLC
17.96
+0.01
+0.06%
ZGNX
1.34
+0.05
+3.88%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Clinical Study Results Presented At The 2015 Gastrointestinal Cancer Symposium Support Utility Of Trovagene’s Precision Cancer Monitoring Platform In Colorectal And Pancreatic Cancer Patients

January 14, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 20, 2015 /PRNewswire/ –Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced the presentation of results from two clinical studies at the 2015 Gastrointestinal Cancer Symposium (also known as ASCO GI…

Neurocrine Biosciences, Inc. Announces Oral Presentation Of NBI-77860 Clinical Trial Data In Classic Congenital Adrenal Hyperplasia At

January 14, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 20, 2015 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrena…

Artists Focus on Sound and Silence from Deaf and Hearing Perspectives

January 14, 2015 – 3:30 pm | Edit Post
Artists Focus on Sound and Silence from Deaf and Hearing Perspectives

At first glance, the title of the Winter 2015 exhibition in the gallery@calit2, LOUD silence, appears to be a contradiction in terms. But for the curator and four artists represented in the exhibition, who are each at a different point on the hearing spectrum, it’s clear that the Deaf have a strong understanding and connection to sound and voice, and that those who have full hearing can appreciate the value and meaning of silence versus the absence of sound.

Parkinson’s stem cell trial approaches

January 14, 2015 – 2:18 pm | Edit Post

A stem cell-based Parkinson’s treatment could soon be tested in Australia.

SDSC Announces UC Graduate Summer Fellowship Program

January 14, 2015 – 11:21 am | Edit Post
SDSC Announces UC Graduate Summer Fellowship Program

The San Diego Supercomputer Center (SDSC) at the University of California, San Diego, has announced its inaugural UC Graduate Student Summer Fellowship program, providing opportunities for graduate students throughout the University of California system to learn about SDSC’s expertise and utilize the Center’s wide range of resources to advance their own research.

Venter signs sequencing deal with Genentech

January 14, 2015 – 8:55 am | Edit Post

Venter calls it “very significant” move in human health.

Houston, Austin, Raleigh, Denver Tops in U.S. for STEM Workers

January 14, 2015 – 8:44 am | Edit Post
Houston, Austin, Raleigh, Denver Tops in U.S. for STEM Workers

All metro areas are not created equal. If you’re looking at job markets in science, technology, engineering, and math (STEM)—a major indicator of economic growth and innovation—the U.S….

[[Click headline to continue reading.]]

Houston, Austin, Raleigh, Denver Tops in U.S. for STEM Workers

January 14, 2015 – 8:44 am | Edit Post

All metro areas are not created equal. If you’re looking at job markets in science, technology, engineering, and math (STEM)—a major indicator of economic growth and innovation—the U.S….

[[Click headline to continue reading.]]

Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples

January 14, 2015 – 8:27 am | Edit Post
Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples

LA JOLLA, Calif., Jan. 14, 2015 /PRNewswire/ — Human Longevity, Inc. (HLI), the human health information technology and health care company, today announced a multi-year agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to conduct whole genome sequencing of tens of thousands of de-identified samples from Genentech. HLI, using proprietary tools and unique expertise, will sequence genomes to 30x coverage and analyze the data. Financial details of the agreement were not disclosed.

“We are excited to be working with Genentech so that patient samples can be analyzed according to more precise genetic categories,” said J. Craig Venter, Ph.D., HLI CEO and Co-Founder.  “At HLI we have built unprecedented capabilities for whole genome sequencing and interpretation to enable a wide array of advances in health care. The application of our capabilities to discover new diagnostics and targeted therapies is one of the most relevant today.”

HLI is focused on building the world’s most comprehensive integrated human genotype and phenotype database, the HLI Knowledgebase™. To achieve that, HLI has established the largest human genome sequencing center in the world, and is sequencing and analyzing complete, 30x coverage genomes using Illumina’s HiSeq X Ten sequencing machines. HLI also utilizes Illumina HiSeq 2500 and Pac Bio RS II instruments.

“Genentech’s goal is to harness the power of widespread whole genome sequencing to identify new therapeutic targets and diagnostic biomarkers,” said James Sabry, senior vice president and global head of Genentech partnering.  “We are pleased to join forces with HLI and leverage their expertise in DNA sequencing and analysis along with scientific expertise to accelerate our drug discovery efforts and ultimately bring to market promising new therapies for patients with serious medical conditions.”

HLI and Genentech take the privacy and protection of individual’s personal information very seriously. All sample and patient data elements are de-identified to remove all personally identifiable information.

About Human Longevity, Inc.
HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world’s most comprehensive knowledge base of human genotypes and phenotypes as a basis for a variety of opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its Knowledgebase™ to pharmaceutical and biotech companies, academic institutions and medical centers, governments, insurers and physicians, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit, www.humanlongevity.com

Logo – http://photos.prnewswire.com/prnh/20140304/LA76169LOGO

SOURCE Human Longevity, Inc.

PlasmaTech Biopharmaceuticals to Present at Biotech Showcase 2015

January 14, 2015 – 7:00 am | Edit Post
PlasmaTech Biopharmaceuticals to Present at Biotech Showcase 2015

DALLAS and NEW YORK, Jan. 14, 2015 /PRNewswire/ — PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting at Biotech Showcase™ 2015 Conference being held in San Francisco, CA this week.  Details are as follows:

Event:

Biotech Showcase™ 2015 Conference

Date: 

Wednesday, January 14, 2015

Time: 

9:30 am Pacific Time

Location:

D-Powell (3rd Floor) Parc 55 Wyndham SF Union Square Hotel

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

About PlasmaTech Biopharmaceuticals, Inc.:  PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care.  Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ as well as multiple pre-clinical follow-on products. For more information visit, www.plasmatechbio.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: timelines and clinical results for MuGard and ProctiGard, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech’s need to obtain additional financing in order to continue clinical trials and operations and to the risks detailed in PlasmaTech’s Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.

Company and Media Contact:
Harrison Wehner
President & CFO
PlasmaTech Biopharmaceuticals, Inc.
(617) 981-6955

SOURCE PlasmaTech Biopharmaceuticals, Inc.